Slides
Page 1
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! Meet AZN Management: ESMO 2026 Investor Event 26 October 2026
Page 2
2 Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in suc h statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to m eet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the risk of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failu re of critical processes; the risk of failure to collect and manage data and artificial intelligence in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet our sustainability targets, regulatory requirements or stakeholder expectations with respect to the environment; the risk of failure to meet regulatory and ethical expectations on commercial practices, including anti-bribery anti- corruption, anti-fraud and scientific exchanges; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property risks related to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global busi ness; the risk of failure in internal control, financial reporting or the occurrence of fraud; and the risk of unexpected deterioration in the Group's financial po sition.
Page 3
3 AstraZeneca @ ESMO 2026 Opening remarks Dave Fredrickson EVP , Oncology Haematology Business Bladder cancer: Expanding the foundational role of Imfinzi across MIBC Including Q&A session Prof. Thomas Powles Professor of Genitourinary Oncology, Barts Cancer Institute EGFRm lung cancer: Extending Tagrissoas backbone therapy Prof. Yi-Long Wu Professor of Oncology, Guangdong Lung Cancer Institute Small cell lung cancer: Reinforcing Imfinzi as backbone therapy across SCLC Leora Horn SVP, Late Development Oncology Gastric cancer: Unlocking the power of ADCs with sone-ve Susan Galbraith EVP , Oncology Haematology R&D Realising our ambition in Oncology Dave Fredrickson EVP , Oncology Haematology Business Looking to the future of AstraZeneca Pascal Soriot Chief Executive Officer Q&A Chaired by Dave Fredrickson EVP , Oncology Haematology Business
Page 4
4 >140 abstract acceptances 38 oral presentations Data spans 27 approved and potential medicines across >15 tumour types Unprecedented 4 Presidential datasets at ESMO at ESMO and WCLC 2026 >110 poster presentations 2 practice-changing Phase III datasets Additional early data driving 2030+ pipeline – DESTINY-Lung04 | Enhertu PL03.081 – SANOVO | Tagrisso + Orpathys LBA69 VOLGA Imfinzi LBA2 SAFFRON Tagrisso + Orpathys LBA6 DeLLphi-305 Imfinzi LBA3 CLARITY-Gastric01 sone-ve LBA7 – torvu-sam FRα ADC | FONTANA 1245RO – rilvegostomig PD-1/TIGIT mAb | ARTEMIDE-01 MO07.101 – AZD7003 GPC3 CAR-T | Phase I update 1680RO 1. Data at WCLC 2026. All other listed datasets are at ESMO 2026. Collaboration partners: Daiichi Sankyo ( Enhertu), Hutchmed (Orpathys). DeLLphi-305 trial is sponsored by Amgen, with partial funding and Imfinzi provided by AstraZeneca. Appendix: Glossary. Featured in Presidential session at congress
Page 5
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! Bladder cancer: Expanding the foundational role of Imfinzi across MIBC Prof. Thomas Powles PROFESSOR OF GENITOURINARY ONCOLOGY, BARTS CANCER INSTITUTE
Page 6
VOLGA – expanding the role of Imfinzi in MIBC Stratification factors – PD-L1 status (high vs low/negative) – Clinical tumour stage (T2N0M0 vs T3-4aN0M0 vs T1-4aN1M0) – Cisplatin status (ineligible vs refusal) EFS was defined as time from randomisation to the first: – Recurrence after RC – Progression in patients who did not receive RC – Failure to undergo RC in patients with residual disease – Death due to any cause 6 Imfinzi dose was 1500 mg, Imjudo dose was 75 mg, and EV dose was 1.25 mg/kg body weight. 1. Evaluated by BICR or central pathology review (if a biopsy was req uired for a suspected new lesion). Powles T et al. Abstract LBA2 presented at the European Society of Medical Oncology 2026. Appendix: Glossary. Dual primary endpoint: – EFS¹: Imfinzi + EV vs control – EFS¹: Imfinzi + Imjudo + EV vs control Key secondary endpoint: – OS: Imfinzi + EV vs control – OS: Imfinzi + Imjudo + EV vs control Other secondary endpoints: – pCR – EORTC QLQ-C30 Exploratory endpoints: – ctDNA analysis Safety – MIBC (cT2- T4aN0/1M0 or cT1N1M0) by local assessment – Ineligible for or refused cisplatin – UC or UC with divergent differentiation or histological subtypes – Evaluated and confirmed for cystectomy Imfinzi + EV N=233 Imfinzi + Imjudo + EV N=233 Control N=229 Imfinzi Q3W × 3 cycles Imfinzi Q3W × 3 cycles Imjudo Q3W × 2 cycles Enfortumab vedotin Q3W × 3 cycles Enfortumab vedotin Q3W × 3 cycles RC Straight to RC Neoadjuvant Imfinzi Q4W × 9 cycles Imfinzi Q4W × 9 cycles Imjudo Q4W × 1 cycle Adjuvant No treatment Observation/locally approved treatment R 1:1:1 N=695
Page 7
VOLGA – Imfinzi + EV demonstrated a statistically significant improvement in EFS vs control 7 Imfinzi + EV N=233 Control N=229 Events, n (%) 84 (36) 123 (54) Median EFS, mo (95% CI) NR (33.2–NC) 12.1 (7.6–27.0) HR (95% CI) 0.51 (0.38–0.67) Stratified log-rank P value1 <0.0001 No. at risk Imfinzi + EV 233 197 180 170 158 136 111 93 80 51 38 21 11 4 1 0 Control 229 157 131 106 98 80 66 59 43 35 22 16 8 5 0 0 Median follow-up2: 23 months 73% 64% 50% 45% Event-free survival (%) 0 0 20 40 60 80 100 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 Time since randomisation (months) EFS is the time from randomisation to the first: 1) recurrence after RC, 2) progression in patients who did not receive RC, 3 ) failure to undergo RC in patients with residual disease, or 4) death due to any cause. 1. The threshold to declare statistical significance was based on a Lan-DeMets alpha spending function with O’Brien -Fleming boundary – with the observed number of events, the boundary for declaring statisti cal significance was 0.0218 for a 2.7% overall 2-sided alpha. 2. In censored patients across all study arms. Data cut-off 02 March 2026. Powles T et al. Abstract LBA2 presented at the European Society of Medical Oncology 2026. Appendix: Glossary.
Page 8
VOLGA – Imfinzi + EV demonstrated a statistically significant improvement in OS vs control 8 Imfinzi + EV N=233 Control N=229 Deaths, n (%) 49 (21) 74 (32) Median OS, mo (95% CI) NR (NC–NC) NR (37.7–NC) HR (95% CI) 0.58 (0.40–0.83) Stratified log-rank P value1 0.0027 87% 78% 81% 69% Median follow-up2: 26 months Overall survival (%) 0 0 20 40 60 80 100 3 6 9 12 15 18 21 24 27 30 33 36 39 42 4845 Time since randomisation (months) No. at risk Imfinzi + EV 233 224 212 207 198 185 160 128 110 82 66 45 27 15 4 0 0 Control 229 208 190 185 176 157 128 110 96 72 53 34 22 13 5 2 0 OS is the time from randomisation until death due to any cause, regardless of whether the patient withdraws from randomised t herapy or receives another anticancer therapy. 1. The threshold to declare statistical significance was based on a Gamma family (-3) spending function – with the observed number of events, the boundary for declaring statistical significance was 0.0104 for a 5% overall 2-sided alpha. 2. In censored patients across all study arms. Data cut -off 02 March 2026. Powles T et al. Abstract LBA2 presented at the European Society of Medical Oncology 2026. Appendix: Glossary.
Page 9
Subgroup Category Imfinzi + EV Control HR (95% CI) All patients 49/233 74/229 0.58 (0.40–0.83) Age at randomisation <65 years 6/49 11/40 NC (NC–NC) ≥65 years 43/184 63/189 0.64 (0.43–0.95) Sex Male 38/191 53/187 0.64 (0.42–0.96) Female 11/42 21/42 0.47 (0.22–0.96) Race White 34/153 45/158 0.71 (0.45–1.10) Non-White 11/56 23/54 0.42 (0.20–0.84) Geographic region Asia 10/44 19/46 0.49 (0.22–1.03) Europe 28/139 37/129 0.61 (0.37–1.00) Americas 11/50 18/54 0.66 (0.30–1.39) Tumour PD-L1 expression1–2 High 27/120 38/120 0.69 (0.42–1.13) Low/negative 22/113 36/109 0.50 (0.29–0.84) Tumour stage1 T2N0M0 19/82 20/83 0.92 (0.49–1.74) T3-4aN0M0 23/113 41/109 0.47 (0.28–0.78) T1-4aN1M0 7/37 12/35 NC (NC–NC) Cisplatin status1 Ineligible 43/175 63/176 0.61 (0.41–0.89) Refusal 6/58 11/53 NC (NC–NC) VOLGA – consistent OS benefit across subgroups 9 0.1 0.2 0.4 1.0 2.00.8 Favours Imfinzi + EV Favours control NC NC Events/patients NC OS HR and CI were not calculated for subgroups with <20 events across both treatment arms. 1. As reported by electronic case report form. 2. Assessed with the clinical trial assay for PD -L1 (SP263) (Roche Diagnostics); high PD-L1 expression was defined as any of the following: ≥25% of tumour cells exhibited membrane staining; or ICP >1% and IC+ ≥25%; or ICP=1% and IC+=100%. Data cut -off 02 March 2026. Powles T et al. Abstract LBA2 presented at the European Society of Medical Oncology 2026. Appendix: Glossary.
Page 10
VOLGA – Imfinzi + EV improved pCR rate vs control, with 60% ctDNA clearance in baseline ctDNA+ patients 10 Local pathology review (ITT)1 0 10 20 30 40 50 60 (105/233) (22/229) 45% (95% CI, 38.6–51.7) 10% (95% CI, 6.1–14.2) Imfinzi + EV (N=233) Control (N=229) Risk ratio, 4.7 (95% CI, 3.1–7.3) pCR rate (%) Exploratory analysis: ctDNA status in matched evaluable samples at baseline and pre-RC = 112 patients2 Pre-RCBaseline Neoadjuvant 78% ctDNA+ (87/112) 32% ctDNA+ (36/112) 22% ctDNA– (25/112) 68% ctDNA– (76/112)60% ctDNA clearance (52/87) 1. Analysis performed using log -binomial models adjusted using stratification factors: PD -L1 status, tumour stage and cisplatin status per interactive-response technology. Patients who did not undergo surgery or those with a missing or non -evaluable assessment were considered non -responders. Data cut-off 02 March 2026. 2. As assessed using Natera's ultrasensitive SignateraTM Genome with Phased and Structural Variants Assay. Analysis based on currently available ctDNA biomarker evaluable population as of July 2026; additional patient data pending. One patient with ctDNA– to ctDNA+ status is not shown in the Sankey plot. Powles T et al. Abstract LBA2 presented at the European Society of Medical Oncology 2026. Appendix: Glossary.
Page 11
Events, n (%) Imfinzi + EV n=228 Control n=229 AEs of any cause 227 (>99) 170 (74) Maximum Grade 3 or 4 AEs 145 (64) 101 (44) Serious AEs 143 (63) 101 (44) Leading to death 17 (7) 14 (6) Leading to discontinuation of any study treatment 48 (21) NA Leading to discontinuation of Imfinzi 37 (16) NA Leading to discontinuation of Imjudo NA NA Leading to discontinuation of enfortumab vedotin 26 (11) NA Leading to cancellation of surgery 2 (0.9) 0 Leading to delay in surgery1 8 (4) 1 (0.4) AEs possibly related to any treatment 207 (91) NA Maximum Grade 3 or 4 AEs 69 (30) NA Serious AEs 45 (20) NA Leading to death 1 (0.4) NA Any-grade immune-mediated AEs 75 (33) 8 (3) Maximum Grade 3 or 4 24 (11) 2 (0.9) Leading to death 0 0 VOLGA – safety profile for Imfinzi + EV consistent with the safety profiles of the individual agents 12 15 19 20 21 21 21 22 24 25 26 32 36 44 3 0.9 0.9 2 2 1 2 8 14 0.9 0.9 8 0.4 3 5 3 6 14 10 21 24 4 1 7 12 50 40 30 20 10 0 10 20 30 40 50 Hypothyroidism Fatigue Dysgeusia Alopecia Asthenia Nausea Rash Decreased appetite Constipation Diarrhoea Anaemia Urinary tract infection Pruritus Patients with AEs (%) Imfinzi + EV arm (n=228) Control arm (n=229) Any grade Grade ≥3 LHS: The safety population includes all patients who received study treatment ( Imfinzi + EV arm) or who were randomised (control arm). Investigator -assessed causality. 1. Recommended timeframe for surgery was withi n 56 days after the last dose of neoadjuvant treatment (Imfinzi + EV arm), and within 12 weeks of diagnosis (control arm). Data cut -off 02 March 2026. RHS: Shows all-causality AEs reported for ≥15% of patients in the safety population for either arm. Data cut -off 02 March 2026. Powles T et al. Abstract LBA2 presented at the European Society of Medical Oncology 2026. Appendix: Glossary.
Page 12
VOLGA – Imfinzi as a foundational treatment across early bladder cancer 13 ― Perioperative Imfinzi + 3 cycles of neoadjuvant enfortumab vedotin significantly improved EFS and OS vs control ― EFS HR 0.51 (95% CI, 0.38–0.67) P<0.0001, and OS HR 0.58 (95% CI, 0.40–0.83) P=0.0027 ― Benefits were consistent across subgroups ― Manageable safety consistent with known profiles, with quality of life maintained after surgery VOLGA supports Imfinzi + enfortumab vedotin as a potential new standard of care for MIBC patients ineligible for, or who refused, cisplatin-based chemotherapy Powles T et al. Abstract LBA2 presented at the European Society of Medical Oncology 2026. Appendix: Glossary.
Page 13
14 Opportunity for Q&A Prof. Thomas Powles PROFE SSOR O F GE NIT OURINARY ONCOL OGY, BAR TS CANCE R INS TIT UT E Key External Expert Pascal Soriot CH IEF E XECUTI VE O FFICE R Dave Fredrickson E VP, ONCOLO GY HAE MATOL OGY BUSINE SS Sunil Verma SVP, GL OBAL HE AD, ONCOL OGY FRANCHIS E Susan Galbraith E VP, ONCOLO GY HAE MATOL OGY R& D Leora Horn SVP, L ATE DEVE LOPMENT ONCOL OGY AstraZeneca Leadership
Page 14
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! EGFRm lung cancer: Extending Tagrisso as backbone therapy Prof. Yi-Long Wu PROFESSOR OF ONCOLOGY, GUANGDONG LUNG CANCER INSTITUTE
Page 15
SAFFRON – Tagrisso + Orpathys potential first biomarker- driven, all-oral therapy for post-TKI EGFRm NSCLC Stratification factors ― Race (Asian/non-Asian) ― Baseline brain metastases (Yes/no) ― Line of treatment (2L/3L) Pemetrexed 500 mg/m2 + carboplatin AUC5/ cisplatin 75 mg/m2 (Q3W for 4 cycles) N = 338 Tagrisso 80 mg QD + Orpathys 300 mg BID4 R 1:1 Primary endpoint: ― PFS (BICR) in the FAS Key secondary/exploratory endpoints: ― PFS (inv.), OS, ORR, DoR, DCR and tumour shrinkage in the FAS ― PFS in the MET-overexpressed and MET-amplified analysis sets ― Safety in the SAS Maintenance pemetrexed 500 mg/m2 (Q3W)4 1. Ex19del, L858R, and/or T790M. 2. Centrally confirmed with post -progression tissue biopsy. MET IHC and FISH cut -offs were identified in preliminary analyses of the Phase II SAVANNAH study. IHC test: Investigational assay for MET (SP44; Roche Diagnostics, Tucson, AZ, USA); FISH test: investigational assay for MET ( Vysis MET FISH Kit; Abbott Molecular, Inc., Des Plaines, IL, USA); 3. Patients treated with Tagrisso in adjuvant spetting were included if progression occurred <6 months after the last dose; 4. Patients received treatment until objective progressive disease by RECIST v1.1 as assessed by investigator, unacceptable toxicity, wit hdrawn consent, or another discontinuation criterion was met; 5. Patients continued to receive Tagrisso plus Orpathys or Tagrisso monotherapy (if Orpathys was stopped earlier) or pemetrexed maintenance beyond RECIST v1.1 -defined progressive disease (if eligible) if they continued t o receive clinical benefit in the opinion of the investigator. Crossover between treatment arms was not allowed. Lu S et al. Abstract LBA6 presented at the European Society of Medical Oncology 2026. Collaboration partner: Hutchmed (Orpathys). Appendix: Glossary. 35% of patients evaluable for MET testing had MET overexpression (IHC3+≥90%) and/or MET amplification (FISH10+) – EGFRm1 locally advanced or metastatic NSCLC – MET overexpression (MET IHC3+≥90%) and/or amplification (FISH10+)2 – Progression on 1L or 2L Tagrisso as the most recent anti-cancer treatment3 Investigator-assessed PD (per RECIST v1.1) or discontinuation Treatment beyond PD allowed per investigator discretion5
Page 16
SAFFRON – Tagrisso + Orpathys significantly improved PFS vs SoC Tagrisso + Orpathys Platinum– pemetrexed Median PFS, mo (95% CI) 7.6 (5.6–9.7) 5.4 (4.2–5.8) HR (95% CI) 0.55 (0.42–0.72) P value p<0.001 100 90 80 70 60 50 Progression-free survival (%) 40 30 20 10 0 0 Tagrisso + Orpathys No. at risk Platinum–pemetrexed 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Time since randomisation (months) 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 171 166 144 124 120 98 82 75 70 64 54 49 39 34 29 25 24 22 21 14 14 8 8 6 5 2 1 1 1 1 1 1 1 1 1 1 1 1 0 167 139 109 87 77 61 43 34 30 22 17 12 8 7 7 4 4 3 3 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 171/117 167/113 Number of patients/number of events 36% 10% Consistent PFS benefit across subgroups 17 Data cut-off: 06 July 2026. Median follow -up for PFS by BICR: Tagrisso + Orpathys 5.6 months, platinum–pemetrexed 3.5 months. Overall maturity: 68%. Lu S et al. Abstract LBA6 presented at the European Society of Medical Oncology 2026. Collaboration partner: Hutchmed (Orpathys). Appendix: Glossary.
Page 17
SAFFRON – significant 4.9-month OS improvement with Tagrisso + Orpathys vs SoC 100 90 80 70 60 50 Overall survival (%) 40 30 20 70% 53% 10 0 0 Tagrisso + Orpathys No. at risk Platinum–pemetrexed 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Time since randomisation (months) 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 Number of patients/number of events 171 170 166 162 157 152 144 138 133 130 119 114 98 93 89 74 63 59 51 46 43 39 31 27 22 17 14 14 13 9 7 6 5 5 3 2 1 1 0 167 154 150 142 137 134 128 119 113 96 86 70 62 51 48 40 36 32 27 23 21 20 20 19 18 18 16 12 11 9 7 4 4 3 2 2 1 1 0 171/87 167/93 Tagrisso + Orpathys Platinum– pemetrexed Median OS, mo (95% CI) 17.8 (15.6–23.7) 12.9 (10.6–16.8) HR (95% CI) 0.68 (0.50–0.91) P value p=0.010 1 18 Data cut-off: 06 July 2026. Median follow -up for OS: Tagrisso + Orpathys 14.2 months, platinum–pemetrexed 10.2 months. Overall maturity: 53%. 1. Boundary to declare statistical significance p<0.03047. Lu S et al. Abstract LBA6 presented at the European Society of Medical Oncology 2026. Collaboration partner: Hutchmed (Orpathys). Appendix: Glossary.
Page 18
SAFFRON – safety profile for Tagrisso + Orpathys consistent with the known profiles of each medicine Tagrisso + Orpathys (n = 170) Platinum– pemetrexed (n = 145) Median total duration of exposure, mo (range) 8.5 (0.7–37.9) 3.5 (0–20.3) TEAEs (all causality), n (%) 169 (99) 140 (97) Any TEAE Grade ≥3 108 (64) 91 (63) Any serious TEAE 69 (41) 40 (28) Any fatal TEAE 12 (7)1 0 Any TEAE leading to discontinuation 23 (14) 12 (8) Any TEAE leading to dose modification 104 (61) 64 (44) TRAEs2, n (%) 158 (93) 134 (92) Any TRAE Grade ≥3 68 (40) 75 (52) Any serious TRAE 24 (14) 23 (16) Any fatal TRAE 1 (1) 0 Any TRAE leading to discontinuation 21 (12) 9 (6) Any TRAE leading to dose modification 82 (48) 55 (38) 4 8 11 12 12 13 15 16 17 18 18 19 21 23 24 25 26 26 49 2 2 1 1 1 3 2 2 2 1 1 8 4 1 5 8 17 17 29 17 26 21 27 16 5 31 29 23 1 8 37 8 54 8 2 10 18 2 1 13 3 9 5 2 1 18 60 40 20 0 20 40 60 Asthenia Neutropenia Decreased neutrophil count Fatigue Decreased appetite Constipation Decreased WBC count Vomiting Increased blood creatinine Decreased platelet count Increased ALT Increased AST Paronychia Hypoalbuminaemia Increased creatine kinase Nausea Diarrhoea Anaemia Peripheral oedema Tagrisso + Orpathys Platinum–pemetrexed Patients (%) Any grade Grade ≥3 19 LHS: Data cut-off: 06 July 2026. 1. Nine of 12 patients in the Tagrisso + Orpathys arm who experienced fatal AEs had either documented disease progression before death or disease progression/NSCLC cited as a primary or secondary cause of death. 2. TRAEs were defined as AEs considered by the investigator to have a reasonable possibility of being caused by the study treatment. R HS: Shows all-causality TEAEs reported for ≥15% of patients in either arm. TEAEs are shown by preferred term. Muscle spasms occurre d in 10% of patients in the Tagrisso + Orpathys arm (Grade ≥3: 0%) and no patients in the platinum–pemetrexed arm. Lu S et al. Abstract LBA6 presented at the European Society of Medical Oncology 2026. Collaboration partner: Hutchmed (Orpathys). Appendix: Glossary.
Page 19
Stratification factors – EGFRm type (ex19del vs L858R) – MET status (IHC 3+ vs IHC 2+) – Brain metastases (yes vs no) – EGFRm untreated unresectable or metastatic NSCLC1 – Centrally confirmed MET overexpression2 – IHC 3+ ≥90%3 or – IHC 2+ (H-score≥220 and <90%)4 R 1:1 Orpathys 300 mg/200 mg BID (by BW) + Tagrisso 80 mg QD Placebo 300 mg/200 mg BID (by BW) + Tagrisso 80 mg QD SANOVO – exploring potential of Tagrisso + Orpathys in 1L setting Until PD or intolerable toxicity 5 1. Patients treated with chemotherapy in neoadjuvant/adjuvant setting were included if progression occurred ≥6 months after t he last dose. EGFRm for inclusion were 19del or L858R. 2. MET IHC kit (D1C2, Amoy Diagnostics, Xiamen, China); 3. IHC 3+: ≥90% of tumour cells demonstrating strong staining; 4. IHC 2+: H -score≥220 and <90% of tumour cells demonstrating strong staining; 5. Pa tients received treatment until objective progressive disease by RECIST 1.1 as assessed by investigator, unacceptable toxicit y, withdrawn consent, or another discontinuation criterion was met. Crossover between treatment groups was not allowed; patients were followed up for safety outcomes 28 days after the last dose of study treatment. Wu Y-L et al. Abstract LBA69 presented at the European Society of Medical Oncology 2026. Collaboration partner: Hutchmed (Orpathys). Appendix: Glossary. N = 326 Primary endpoint: ― PFS (inv.) Secondary endpoints: ― PFS (IRC), ORR, DoR, DCR (inv. and IRC), OS ― Safety 60% of the enrolled population had IHC 3+, the remainder were IHC 2+ CHINA ONLY TRIAL
Page 20
Progression-free survival (%) Time since randomisation (months) 76.0% 53.7% 47.0% 28.3% 0 4 8 12 16 20 24 28 32 36 40 44 48 98 91 82 53 47 41 36 23 13 7 4 2 0 98 74 59 37 31 23 20 16 11 5 0 No. at risk Tagrisso + Orpathys Tagrisso 100 90 80 70 60 50 40 30 20 10 0 Progression-free survival (%) 74.6% 54.9% 54.9% 30.3% Time since randomisation (months) 0 4 8 12 16 20 24 28 32 36 40 44 48 162 149 134 98 87 77 69 48 33 22 13 3 0 164 132 107 80 67 46 42 36 29 21 7 3 0 No. at risk Tagrisso + Orpathys Tagrisso 100 90 80 70 60 50 40 30 20 10 0 SANOVO – Tagrisso + Orpathys significantly improved PFS1 IRC-assessed PFS benefit was consistent with investigator assessment MET IHC 3+ population ITT population Tagrisso + Orpathys N = 98 Tagrisso N = 98 mPFS (95% CI), mo 24.8 (19.4–27.6) 11.1 (8.3–16.6) HR (95% CI) P value 0.45 (0.31–0.66) p<0.0001 Tagrisso + Orpathys N = 162 Tagrisso N = 164 mPFS (95% CI), mo 24.9 (22.0–27.6) 13.8 (10.9–16.6) HR (95% CI) P value 0.56 (0.43–0.74) p<0.0001 21 1. PFS by investigator assessment. Median follow -up for PFS: 30.4 months in the MET IHC 3+ population and 38.6 months in the ITT population. Wu Y-L et al. Abstract LBA69 presented at the European Society of Medical Oncology 2026. Collaboration partner: Hutchmed (Orpathys). Appendix: Glossary.
Page 21
SANOVO – very encouraging clinical benefit in overall survival with Tagrisso + Orpathys 94.4% 81.0% 79.8% 65.4% 67.4% 47.4% Time since randomisation (months) 0 4 8 12 16 20 24 28 32 36 40 44 48 162 158 156 142 123 114 109 105 82 57 45 8 0 164 153 144 121 102 93 90 80 62 47 33 4 0 No. at risk Tagrisso + Orpathys Tagrisso 100 90 80 70 60 50 40 30 20 10 0 Probability of OS (%) Tagrisso + Orpathys N = 162 Tagrisso N = 164 Number of deaths, n (%) 1–2 49 (30.2) 83 (50.6) Median OS, mo (95% CI) 44.5 (41.3–NE) 34.9 (26.3–41.1) HR (95% CI) 0.48 (0.33–0.68) 22 1. At the data cut-off date, the overall survival maturity was 40.5%. 2. Median follow -up for OS: 38.7 months (ITT population). Wu Y-L et al. Abstract LBA69 presented at the European Society of Medical Oncology 2026. Collaboration partner: Hutchmed (Orpathys). Appendix: Glossary.
Page 22
SANOVO – safety remains consistent with known profiles 23 RHS: Shows all-causality TEAEs reported for ≥25% of patients in either arm. Wu Y-L et al. Abstract LBA69 presented at the European Society of Medical Oncology 2026. Collaboration partner: Hutchmed (Orpathys). Appendix: Glossary. Tagrisso + Orpathys N = 162 Tagrisso N = 164 Median exposure, mo (range) 22.1 (0.4–44.2) 12.9 (0.4–45.5) Any TEAE, n (%) 162 (100.0) 163 (99.4) Grade ≥3 TEAE 125 (77.2) 63 (38.4) TEAE leading to dose modification 119 (73.5) 57 (34.8) TEAE leading to discontinuation 24 (14.8) 7 (4.3) Serious TEAE 89 (54.9) 47 (28.7) Fatal TEAE (excluding PD) 7 (4.3) 8 (4.8) 23 25 27 27 30 35 38 39 41 41 42 45 45 47 49 51 63 65 1 9 7 2 1 1 2 2 7 4 4 7 6 2 1 7 25 16 18 12 16 23 38 30 10 27 25 33 29 23 40 32 22 7 1 4 2 1 1 1 2 1 2 2 80 60 40 20 0 20 40 60 80 Weight decreased Nausea Lymphocyte count decreased Hypokalaemia Mouth ulceration Decreased appetite Diarrhoea Rash Hypocalcaemia ALT increased Neutrophil count decreased White blood cell count decreased AST increased Blood creatinine increased Anaemia Platelet count decreased Hypoalbuminaemia Peripheral oedema Tagrisso + Orpathys Tagrisso Patients (%) Any grade Grade ≥3
Page 23
SAFFRON and SANOVO – reinforcing role of backbone Tagrisso across lines of treatment for EGFRm NSCLC Tagrisso + Orpathys establishes a potential new oral standard-of-care for biomarker-directed EGFRm advanced NSCLC ― SAFFRON: Tagrisso + Orpathys demonstrated statistically significant and clinically meaningful improvements in PFS and OS vs platinum–pemetrexed in EGFRm MET-overexpressed and/or -amplified post-TKI advanced NSCLC1 ― SANOVO: Tagrisso + Orpathys showed statistically significant and clinically meaningful improvements in PFS vs Tagrisso alone in untreated advanced NSCLC patients harbouring activating EGFRm and MET overexpression in China-only trial2 ― Combination in both trials demonstrated a tolerable safety profile, which was consistent with the established profiles for each treatment1,2 24 1. Lu S et al. Abstract LBA6 presented at the European Society of Medical Oncology 2026. 2. Wu Y -L et al. Abstract LBA69 presented at the European Society of Medical Oncology 2026. Collaboration partner: Hutchmed (Orpathys). Appendix: Glossary.
Page 24
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! Small cell lung cancer: Reinforcing Imfinzi as backbone therapy across SCLC Leora Horn SVP, LATE DEVELOPMENT ONCOLOGY
Page 25
DeLLphi-305 – further reinforcing key role of Imfinzi in ES-SCLC with new data in combination with Imdelltra® 26 Data cut-off date: 7 July 2026. 1. Eligible patients must have received ≥3 cycles of concomitant Imfinzi as 1L treatment of ES-SCLC. 2. Patients were monitored on site for a minimum of 1 to 2 hours, or 6 to 8 hours in certain region s after the first two doses of Imdelltra®. 3. Each treatment cycle consists of 28 days. Sands J et al. Abstract LBA3 presented at the European Society of Medical Oncology 2026. DeLLphi -305 trial is sponsored by Amgen , with partial funding and Imfinzi provided by AstraZeneca. Appendix: Glossary. Imfinzi1 + platinum- etoposide induction therapy (4 cycles) ― Age ≥18 years ― No disease progression ― ECOG PS 0–1 ― Asymptomatic untreated or treated brain metastases R 1:1 N=563 Until progression or unacceptable toxicity Imfinzi (1500 mg Q4W)3 + Imdelltra® (tarlatamab) (10 mg Q2W)2 | n=282 Imfinzi (1500 mg Q4W)3 n=281 Primary endpoint ― OS Key secondary endpoint ― PFS Secondary endpoints ― ORR ― DoR ― Safety Stratification factors ― Brain and/or liver metastases (yes/no) ― Response to 1L CTx–IO (PR/CR vs SD) ― Prior platinum type (cisplatin vs carboplatin) Interim OS analysis: 243 (61% IF) OS events Two-sided P-value boundary: 0.008 Endpoints were tested sequentially according to prespecified hierarchical testing strategy: OS, then PFS, then ORR
Page 26
DeLLphi-305 – significant OS improvement with Imfinzi + Imdelltra® vs Imfinzi alone 92% 75% 79% 53% 0 20 40 60 80 100 Overall survival (%) 0 3 6 9 12 15 18 21 24 27 Time since randomisation (months) 282 276 258 246 222 132 55 9 0 No. at risk Imfinzi + Imdelltra® Imfinzi 281 252 208 171 146 81 33 8 1 0 Imfinzi + Imdelltra® (n=282) Imfinzi (n=281) Median OS, mo (95% CI) 21.1 (20.8–NE) 12.7 (11.2–14.8) HR (95% CI) 0.42 (0.32–0.54) P value (2-sided) <0.001 27 Data cut-off date: 7 July 2026. At the time of data cut-off, 87 events had occurred in the Imfinzi-Imdelltra® arm, and 156 events had occurred in the Imfinzi arm. Median follow -up 15.9 mo for Imfinzi + Imdelltra® and 16.1 mo for Imfinzi. P-value calculated using a stratified log -rank test. Sands J et al. Abstract LBA3 presented at the European Society of Medical Oncology 2026. DeLLphi -305 trial is sponsored by Amgen, with partial funding and Imfinzi provided by AstraZeneca. Appendix: Glossary.
Page 27
DeLLphi-305 – more than 5-month PFS improvement with Imfinzi + Imdelltra® vs Imfinzi alone 53% 38% 17% 10% 0 20 40 60 80 100 Progression-free survival (%) 0 3 6 9 12 15 18 21 24 Time since randomisation (months) No. at risk Imfinzi + Imdelltra® 282 225 147 122 86 32 14 1 0 Imfinzi 281 106 46 36 18 8 2 0 Imfinzi + Imdelltra® (n=282) Imfinzi (n=281) Median PFS, mo (95% CI) 7.4 (5.6–9.1) 1.9 (1.9–2.0) HR (95% CI) 0.34 (0.28–0.42) P value (2-sided) <0.001 28 Data cut-off date: 7 July 2026. At the time of data cut-off, 182 events had occurred in the Imfinzi-Imdelltra® arm, and 250 events had occurred in the Imfinzi arm. Median follow -up 13.9 mo for Imfinzi + Imdelltra® and 13.9 mo for Imfinzi. P-value calculated using a stratified log -rank test. Sands J et al. Abstract LBA3 presented at the European Society of Medical Oncology 2026. DeLLphi -305 trial is sponsored by Amgen, with partial funding and Imfinzi provided by AstraZeneca. Appendix: Glossary.
Page 28
DeLLphi-305 – manageable safety profile consistent with the individual agents Events, n (%) Imfinzi + Imdelltra® (n=282) Imfinzi (n=278) Median treatment duration, weeks (IQR) 46.9 (16.4–65.6) 8.1 (4.1–20.1) Any TEAE 281 (99.6) 258 (92.8) Grade ≥3 TEAE 132 (46.8) 113 (40.6) Serious TEAE 118 (41.8) 88 (31.7) Fatal TEAE 13 (4.6) 13 (4.7) TEAE leading to Imdelltra® discontinuation 16 (5.7) NA TEAE leading to Imfinzi discontinuation 16 (5.7) 16 (5.8) Any TRAE1 268 (95.0) 145 (52.2) Grade ≥3 TRAE 59 (20.9) 30 (10.8) Serious TRAE 63 (22.3) 26 (9.4) Fatal TRAE 0 (0.0) 2 (0.7) TRAE leading to Imdelltra® discontinuation 9 (3.2) NA TRAE leading to Imfinzi discontinuation 9 (3.2) 10 (3.6) – CRS and ICANS consistent with the known safety profile of Imdelltra®2 – Most CRS events resolved with supportive care and antipyretics – Interventions included corticosteroids (21.6%), tocilizumab (3.9%) and low- flow oxygen (1.4%) 29 1. Related to any treatment. 2. CRS and ICANS events were graded using ASTCT 2019 criteria. Data cut-off date: 7 July 2026. Assessed by investigator. Grade ≥3 TRAEs in ≥1% included decreased neutrophil count, neutropenia and decreased appetite with Imfinzi + Imdelltra®, and pneumonitis, increased AST and increased lipase with Imfinzi. Treatment discontinuations were infrequent, with no treatment -related fatalities in the combination arm. Sands J et al. Abstract LBA3 presented at the European Society of Medical Oncology 2026. DeLLphi -305 trial is sponsored by Amgen, with partial funding and Imfinzi provided by AstraZeneca. Appendix: Glossary.
Page 29
DeLLphi-305 – Imfinzi + Imdelltra® first dual IO regimen in ES-SCLC, reinforcing the role of Imfinzi in this setting ― Imfinzi + Imdelltra® significantly improved OS, PFS and ORR vs Imfinzi in patients with ES-SCLC without progression after initial CTx + Imfinzi ― 58% reduction in the risk of death ― 66% reduction in the risk of disease progression or death ― Survival benefit extended to all predefined subgroups, including patients with brain metastases, liver metastases or minimal response to initial CTx + Imfinzi ― Imfinzi + Imdelltra® demonstrated a manageable safety profile with low rates of treatment discontinuation due to adverse events DeLLphi-305 outcomes support maintenance therapy with Imfinzi + Imdelltra® as a new standard of care for first-line patients post-induction with Imfinzi + chemotherapy 30 Sands J et al. Abstract LBA3 presented at the European Society of Medical Oncology 2026. DeLLphi -305 trial is sponsored by Amgen , with partial funding and Imfinzi provided by AstraZeneca. Appendix: Glossary.
Page 30
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! Gastric cancer: Unlocking the power of ADCs with sone-ve Susan Galbraith EVP, ONCOLOGY HAEMATOLOGY R&D
Page 31
Rapidly advancing broad high-value portfolio of ADCs 32 Clinical-stage ADC pipeline spans multiple targets across solid and haematologic tumour types Phase I Phase II Phase III B7-H4 TOP1i | puxi-sam FRα TOP1i | torvu-sam GPRC5D MMAE | AZD0305 CLDN18.2 MMAE | sone-ve STEAP2 TOP1i | AZD0516 CD22 TOP1i | AZD4512 Expanding Phase III development for late- stage ADCs Ongoing To be initiated 6 wholly owned ADCs in clinic Preclinical pipeline including dual payload ADCs Ongoing FSI Q3’26 FSI Q3’26 NEW HLR H2’27 sone-ve torvu-sam puxi-sam NEW Appendix: Glossary. CLARITY-Gastric01 2L+ Claudin 18.2+ gastric cancer CLARITY-Gastric02 1L Claudin 18.2+ gastric cancer + ivonescimab GI cancers TREVI-OC-01 FRα-high and -low PRR ovarian cancer TREVI-OC-03 PSR ovarian cancer (maintenance) TREVI-OC-02 1L HRD-ve ovarian cancer (maintenance) Bluestar-Endometrial01 2L+ B7-H4 endometrial cancer
Page 32
Enhancing the value of AstraZeneca’s ADC portfolio through strategic collaboration with Summit 33 Positions AstraZeneca as a leader in the ADC + next-generation IO bispecific space – Broadens and maximises AZ assets across key tumour types by addressing segmented treatment approaches – Strategic investment in Summit accelerates development of ivonescimab + ADCs across tumour types sone-ve + ivonescimab Datroway + ivonescimab Other AZ assets + ivonescimab Gastrointestinal cancers Breast and lung cancers Planned collaboration Collaboration partner: Daiichi Sankyo ( Datroway). Appendix: Glossary.
Page 33
Maximising the potential of AstraZeneca ADCs through combinations with next-generation IO bispecifics 34 Illustrative of ADC value only; not to scale Monotherapy and current standard-of-care combinations Next generation IO bispecific combinations AZ-owned Through external partnership1 Monotherapy, small molecules, mAbs, PD-1/PD-L1 mAbs Maximisation with next-generation IO Early leadership with monotherapy and combinations with SoC 1. External collaboration with Summit Therapeutics to investigate combinations of ivonescimab and AZ ADCs. Signed collaborations for Datroway and sone-ve. Appendix: Glossary.
Page 34
CLARITY-Gastric01 – establishing sone-ve in gastric cancer with positive overall survival data Study population: – 2L+ GEC expressing CLDN18.2 (≥25% tumour cells with any intensity membranous staining) Dual primary endpoints: – OS (3L+2) – PFS by BICR (ITT 3) Key secondary endpoint: – OS (ITT) Additional secondary /exploratory endpoints: – PFS by BICR (3L+) – ORR and DoR by BICR (ITT , 3L+) – Safety – OS by CLDN18.2 expression (ITT) – PFS, ORR and DoR by Investigator (ITT, 3L+) – OS in prespecified subgroups (ITT , 3L+) sone-ve 2.2 mg/kg Q3W (n=267) Investigator’s choice of therapy (n=265) 4 sone-ve 1.8 mg/kg Q3W (n=62): closed to enrolment DOSE SELECTION R 1:1:11 R 1:1 Stratification factors – Region – Prior gastrectomy – Treatment line Multiple testing procedure DUAL PRIMARY PFS in ITT 3 0.1% initial alpha OS in 3L+ 2 4.9% initial alpha OS in ITT 2-sided α recycling 35 1. Patients were randomised 1:1:1 to sone-ve 2.2 mg/kg Q3W, sone-ve 1.8 mg/kg Q3W, or investigator’s choice of therapy. As of January 2025, the optimal sone -ve monotherapy dose was determined to be 2.2 mg/kg IV Q3W and the 1.8 mg/kg arm was closed to enrolment. Randomisation continued in a 1:1 ratio sone -ve 2.2 mg/kg Q3W or investigator’s choice of therapy. 2. All randomised patients who had received ≥2 prior lines of systemic the rapy; 3. All randomised patients who had received ≥1 prior line of systemic therapy. 4. Investigator’s choice of therapy in 2L: ramucirumab plus paclitaxel, paclitaxel (patients with contraindication t o ramucirumab only), docetaxel (patients with contraindication to ramucirumab only); Investigator’s choice of therapy in 3L: iri notecan, trifluridine/tipiracil (except China), apatinib (China only). Xu R-H et al. Abstract LBA7 presented at the European Society of Medical Oncology 2026. Appendix: Glossary. N=594
Page 35
OS HR point estimates favoured sone-ve vs ICT across all clinically relevant subgroups in the 3L+ population sone-ve 2.2 mg/kg (n=178) Investigator's choice of therapy (n=177) Median OS, mo (95% CI) 10.0 (7.2–11.4) 5.0 (4.2–6.4) HR (95% CI) 0.47 (0.36–0.62) P value <0.000001 No. at risk sone-ve 178 146 95 59 19 7 3 1 0 0 ICT 177 117 58 24 14 6 2 2 1 0 0 3 6 9 12 15 18 2721 24 0 10 20 30 40 50 60 70 80 90 100 Overall survival (%) Time since randomisation (months) CLARITY-Gastric01 – sone-ve reduced the risk of death by 53% vs investigator’s choice of therapy in 3L+ 36 The HR for event or death and CI were estimated from a stratified Cox proportional -hazards model with ties = Efron. Stratificati on variables included geographical region, prior gastrectomy and line of therapy. The CI was calculated using a profile likeliho od approach. An HR of less than 1 favours sone -ve. Tick marks indicate censored observations. Xu R-H et al. Abstract LBA7 presented at the European Society of Medical Oncology 2026. Appendix: Glossary. 18.1% 38.1%
Page 36
CLARITY-Gastric01 – sone-ve reduced the risk of death by 42% vs investigator’s choice of therapy in 2L+ 37 The HR for event or death and CI were estimated from a stratified Cox proportional -hazards model with ties = Efron. Stratificati on variables included geographical region, prior gastrectomy and line of therapy. The CI was calculated using a profile likeliho od approach. An HR of less than 1 favours sone -ve. Tick marks indicate censored observations. Xu R-H et al. Abstract LBA7 presented at the European Society of Medical Oncology 2026. Appendix: Glossary. sone-ve 2.2 mg/kg (n=267) Investigator's choice of therapy (n=265) Median OS, mo (95% CI) 10.6 (9.1–12.0) 6.4 (5.8–7.6) HR (95% CI) 0.58 (0.47–0.73) P value 0.000004 No. at risk sone-ve 267 227 159 107 49 26 14 6 1 0 ICT 265 197 114 67 37 14 8 5 1 0 0 3 6 9 12 15 18 2721 24 0 10 20 30 40 50 60 70 80 90 100 Overall survival (%) Time since randomisation (months) Consistent OS benefit across CLDN18.2 expression levels (≥75% and ≥25% to <75%) in 2L+ population (exploratory endpoint) 42.6% 27.8%
Page 37
Subgroup No. of events/total no. of patients HR (95% CI)sone-ve 2.2 mg/kg Investigator’s choice of therapy All patients 139/267 (52.1) 174/265 (65.7) 0.58 (0.47–0.73) Age: ≥18–<65 years 96/191 (50.3) 123/192 (64.1) 0.60 (0.46–0.78) Age: ≥65 years 43/76 (56.6) 51/73 (69.9) 0.64 (0.42–0.96) Sex: Female 52/117 (44.4) 62/106 (58.5) 0.58 (0.40–0.84) Sex: Male 87/150 (58.0) 112/159 (70.4) 0.64 (0.48–0.85) Region: Japan and South Korea 22/55 (40.0) 33/54 (61.1) 0.52 (0.30–0.89) Region: Other Asia 59/107 (55.1) 83/106 (78.3) 0.46 (0.33–0.64) Region: RoW 58/105 (55.2) 58/105 (55.2) 0.92 (0.64–1.33) ECOG PS: 0 43/88 (48.9) 46/92 (50.0) 0.80 (0.53–1.22) ECOG PS: 1 96/179 (53.6) 128/173 (74.0) 0.53 (0.40–0.69) Primary tumour location: Gastric 106/213 (49.8) 133/194 (68.6) 0.52 (0.40–0.67) Primary tumour location: Gastro-oesophageal junction or oesophageal adenocarcinoma 33/54 (61.1) 41/71 (57.7) 1.08 (0.68–1.71) No. of organ metastases: 0–2 84/179 (46.9) 112/185 (60.5) 0.63 (0.47–0.83) No. of organ metastases: 3 55/88 (62.5) 62/80 (77.5) 0.53 (0.37–0.77) Liver metastasis: Yes 40/66 (60.6) 55/74 (74.3) 0.60 (0.40–0.90) Liver metastasis: No 99/201 (49.3) 119/191 (62.3) 0.62 (0.47–0.81) Peritoneal metastasis: Yes 87/163 (53.4) 108/148 (73.0) 0.50 (0.37–0.66) Peritoneal metastasis: No 52/104 (50.0) 66/117 (56.4) 0.78 (0.54–1.12) Prior gastrectomy: Yes 49/110 (44.5) 70/111 (63.1) 0.45 (0.31–0.65) Prior gastrectomy: No 90/157 (57.3) 104/154 (67.5) 0.76 (0.57–1.01) Line of therapy: 2L 54/89 (60.7) 52/88 (59.1) 0.88 (0.60–1.30) Line of therapy: 3L+ 85/178 (47.8) 122/177 (68.9) 0.47 (0.36–0.62) CLARITY-Gastric01 – exploratory analysis shows favourable OS HR point estimates across most subgroups in 2L+ 38 All subgroups were pre-specified in the protocol. The analysis was based on the Kaplan -Meier technique and was performed using a n unstratified Cox proportional hazards model. The overall HR was calculated using a stratified Cox proportional hazards mode l, adjusting for Interactive Response Technology strata, including prior gastrectomy, region and line of therapy and using an im plemented pooling strategy per the statistical analysis plan with treatment as the only covariate. Ties were handled by the Efron approach. CIs were calculated using a profile likelihood approach. An HR below 1 favours sone-ve. Because PFS and OS were the only endpoints that were part of the multiple testing procedure, the widths of the CIs for subg roups have not been adjusted for multiplicity and may not be used in place of hypothesis testing. The grey band represents the 95% CI for the HR calculated fo r all patients. Xu R-H et al. Abstract LBA7 presented at the European Society of Medical Oncology 2026. Appendix: Glossary. 10 2 Favourssone-ve 2.2 mg/kg Favours investigator’s choice of therapy
Page 38
sone-ve was associated with a manageable safety profile with a lower incidence of Grade ≥3 AEs than investigator’s choice of therapy sone-ve (n=261) Investigator’s choice of therapy (n=252) Any grade Grade ≥3 CLARITY-Gastric01 – differentiated and manageable safety profile vs ICT 39 Safety was assessed in all patients who received ≥1 treatment dose. Treatment -emergent AEs began or worsened from first dose thr ough 97 days after the last dose, or until the day before subsequent cancer therapy, whichever occurred first; patients were counted once per AE category. The 10 most common any -Grade and Grade ≥3 AEs are shown. *Possibly treatment -related AEs were those considered by the investigator to have a reasonable possibility of being caused by treatment; missing responses were counted as possibly related. †Fatal AEs: sone -ve—pneumonia, cholestatic jaundice and cardiac failure; investigator’s choice —pulmonary embolism and abdominal infection. Peripher al neuropathy occurred in 21.5% versus 14.3% of patients (Grade ≥3: 0.8% versus 0.4%), and alopecia in 5.0% versus 14.3%, respectively. AE, adverse event; CTCAE, Common Terminology Criteria for Adve rse Events; SAE, serious adverse event. Xu R-H et al. Abstract LBA7 presented at the European Society of Medical Oncology 2026. Appendix: Glossary. 21.8% 23.0% 23.8% 24.1% 24.5% 28.0% 29.9% 41.0% 43.3% 54.4% 3.1% 3.4% 4.2% 6.9% 10.3% 4.2% 3.4% 8.4% 6.1% 9.6% 6.9% 14.7% 25.4% 39.7% 19.8% 13.1% 11.9% 40.9% 24.6% 24.2% 26.6% 3.2% 2.8% 1.6% 18.7% 25.4% 3.6% 0.8% 11.1% 2.8% 1.6% 2.8% 80 60 40 20 0 20 40 60 80 Lymphocyte count decreased Pneumonia Pulmonary embolism Neutrophil count decreased Hypoalbuminaemia Diarrhoea Neutropenia Fatigue Constipation Weight decreased Anaemia Vomiting Decreased appetite Nausea Patients (%) Sone-Ve 2.2 mg/kg (n=261) Investigator’s choice of therapy (n=252) Median (range) duration of exposure, months 3.9 (0.2–24.7) 2.1 (0.2–22.0) Any AE, n (%) 254 (97.3) 237 (94.0) Possibly related to treatment,* n (%) 224 (85.8) 205 (81.3) Any AE of CTCAE Grade ≥3, n (%) 138 (52.9) 154 (61.1) Possibly related to treatment,* n (%) 95 (36.4) 113 (44.8) Any SAE, n (%) 91 (34.9) 79 (31.3) Any AE leading to discontinuation of study treatment, n (%) 13 (5.0) 11 (4.4) Possibly related to study treatment,* n (%) 8 (3.1) 11 (4.4) Any AE leading to interruption of study treatment or dose delay, n (%) 95 (36.4) 102 (40.5) Any AE leading to dose reductions, n (%) 55 (21.1) 58 (23.0) Any AE with outcome of death, n (%) 11 (4.2) 6 (2.4) Possibly related to treatment,*† n (%) 3 (1.1) 2 (0.8)
Page 39
CLARITY-Gastric01 – sone-ve improves OS with a manageable safety profile in the 2L+ setting ― sone-ve significantly improved OS vs investigator’s choice of therapy in advanced or metastatic CLDN18.2-positive gastro-oesophageal carcinoma ― 53% reduction in the risk of death in 3L+ and 42% in 2L+ ― Median OS improved by over 4 months to 10.6 months in 2L+ and doubled to 10.0 months in 3L+ ―Consistent OS benefit across CLDN18.2 expression levels (≥75% and ≥25% to <75%) ― PFS by BICR in 2L+ did not reach statistical significance; PFS by investigator (exploratory) showed pronounced treatment effect (HR 0.59) ― sone-ve demonstrated a differentiated, manageable safety profile with lower rates of Grade ≥3 AEs and haematologic toxicities vs ICT sone-ve may set a new standard of care in the 2L+ setting for patients with advanced or metastatic CLDN18.2-positive (≥25%) gastro-oesophageal carcinoma 40 Xu R-H et al. Abstract LBA7 presented at the European Society of Medical Oncology 2026. Appendix: Glossary.
Page 40
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! Realising our ambition in Oncology Dave Fredrickson EVP, ONCOLOGY HAEMATOLOGY BUSINESS
Page 41
Transforming treatment in CLDN18.2+ gastric cancers 42 Moving earlier and broader with sone-ve CLARITY-Gastric01 represents potential blockbuster opportunity 2 1L metastatic gastric cancer CLARITY-Gastric02 Phase III ongoing | >2027 BTC and pancreatic cancer CLARITY-PanTumour01 Phase II ongoing | H1 2027 CLARITY-Gastric01 | First global study to show OS benefit in broad 2L+ CLDN18.2+ population Lower CLDN18.2+ cut- off doubles eligibility vs existing therapies $3-5bn PYR opportunity across indications2 >50k patients across the G7 >200k patients in China 60% | CLDN18.2 expression ≥25% CLARITY-Gastric01 sone-ve 2L+ HER2-negative gastric cancer + ivonescimab3 | GI cancers 1. Xu R-H et al. Abstract LBA7 presented at the European Society of Medical Oncology 2026. 2. Peak Year Revenue, non -risk-adjusted. 3. External collaboration with Summit Therapeutics to investigate combinations of ivonescimab and AZ ADCs. Signed collaborations for Datroway and sone-ve. Appendix: Glossary. >40% Data support rapid adoption upon approval, with first-mover advantage in G7 markets OS risk reduction vs SoC in 2L+1
Page 42
1. Top 8 countries. 2. Non-risk adjusted peak year revenue opportunity for Imfinzi bladder programme. Appendix: Glossary. 43 VOLGA reinforces Imfinzi as a backbone in bladder cancer VOLGA | Consolidating the role of Imfinzi across the spectrum of MIBC NMIBC MIBC Imfinzi + BCG induction and maintenance POTOMAC 45% high risk Datroway +/- rilvegostomig TROPION-Urothelial04 ~20% high -risk adjuvant Expanding presence in bladder cancer with broad Imfinzi coverage Competitive space with multiple options Large MIBC market with >100k patients1 Patient-focused, differentiated regimen Strong efficacy with EV exposure only in neoadjuvant setting Established HCP base HCP experience built on NIAGARA's first- to-market approval in cis-eligible MIBC Imfinzi in bladder cancer represents blockbuster opportunity2 VOLGA Neoadj. Imfinzi + EV → adj. Imfinzi NIAGARA Neoadj. Imfinzi + CTx → adj. Imfinzi
Page 43
Strengthening position in EGFRm NSCLC with Tagrisso + Orpathys combinations 44 Results reinforce Tagrisso as the backbone therapy across EGFRm lung cancer supporting continued EGFRm franchise growth SAFFRON | Only global trial to demonstrate significant OS in this setting 45k patients across the G7 210k patients in China 34% | SAFFRON Tagrisso + Orpathys Biomarker-directed, all-oral therapy | 2L+ NSCLC MET overexpression IHC 3+ or amplification FISH 10+ Tagrisso combination pipeline ensures continued leadership TROPION-Lung14 Datroway + Tagrisso Datroway ± Tagrisso Tagrisso + Orpathys TROPION-Lung15 Establishing novel combinations in 2L+ SANOVO H1 2027 >2027 Expanding 1L disease leadership All numbers are approximate. Illustrative settings and populations, not to scale. Collaboration partners: Daiichi Sankyo ( Datroway), Hutchmed (Orpathys). Appendix: Glossary.
Page 44
AstraZeneca in EGFRm non-small cell lung cancer 45 Exon 20 insertion mutations ~10% Exon 19 deletions / exon 21 L858R mutations ~75% Other mutations ~15% MetastaticUnresectableResectable Stg. I 1st line 2nd line +Stg. I-II Stg. IIIStg. II-III ~28K ~51K~9K ~15K~11K ~43K launched and established SoC launched indication DXd ADC IO TKI IO bispecificKey: SBRT → Tagrisso PACIFIC-4 Tagrisso ADAURA2 Tagrisso ADAURA CRT → Tagrisso LAURA Zegfrovy WU-KONG283 Tagrisso +/- CTx FLAURA, FLAURA2 Datroway + Tagrisso TROPION-Lung14 Tagrisso + Orpathys SANOVO1 MET-driven 10-15%2 Zegfrovy WU-KONG1B3 Datroway ± Tagrisso TROPION-Lung15 Tagrisso + Orpathys SAFFRON Datroway TROPION-Lung05 MET-driven 34%2 Est. epi (G7, 2026) 1. China-only trial. 2. MET-driven defined as MET IHC 3+ in 1L and MET IHC 3+ or FISH 10+ in 2L. 3. Trial sponsored by Dizal Pharma. All numbers are approximate. Illustrative settings and populations, not to scale. Lung Cancer map reflects Phase III/pivotal trials. Collaboration partners: Daiichi Sankyo ( Enhertu, Datroway), Hutchmed (Orpathys). Appendix: Glossary. Zegfrovy WU-KONG161,3
Page 45
Continuing to reshape management of SCLC with Imfinzi-based regimens 46 DeLLphi-305 | First dual IO regimen and potential new SoC in ES-SCLC Limited-stage SCLC Extensive-stage SCLC CRT → Imfinzi ADRIATIC CRT → Imfinzi + Imdelltra® PrE0512 CTx + Imfinzi → Imfinzi CASPIAN CTx + Imfinzi → Imfinzi + Imdelltra® DeLLphi-305 CTx + Imfinzi + Imdelltra® → Imfinzi + Imdelltra® DeLLphi-312 Ongoing development programme for Imfinzi in SCLC Blockbuster opportunity for Imfinzi Incremental to CASPIAN High unmet need Current survival outcomes remain ~1 year Significant patient population 195k patients with 1L ES-SCLC1 Imfinzi only IO with proven OS benefit across all stages of SCLC 1,. Top 8 countries. DeLLphi-305 trial is sponsored by Amgen, with partial funding and Imfinzi provided by AstraZeneca. Appendix: Glossary. Amgen-led trialPrECOG-led trial
Page 46
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! Looking to the future of AstraZeneca Pascal Soriot CHIEF EXECUTIVE OFFICER
Page 47
Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth Working on “today, tomorrow and the day after” 48 2023 2030 $45.8bn IRA impact Loss of Exclusivity Existing portfolio Calquence Enhertu Imfinzi/Imjudo Tagrisso Truqap Airsupra Breztri Fasenra Lokelma Saphnelo Tezspire Wainua Ultomiris Launching key NMEs AZD0120 Etcamah Datroway rilvegostomig saruparib surovatamig volrustomig AZN ADCs efzimfotase alfa Klygefa eneboparatide $80bn ADCs and Radioconjugates Cell therapy and T-cell engagers Gene therapy Next-generation IO bispecifics Weight management and CV risk factors Beyond 2030 Brilinta Farxiga Lynparza Soliris Illustrative only, not to scale 2030 Total Revenue ambition not dependent upon future M&A laroprovstat tozorakimab zibo/Farxiga balci/dapa Baxfendy baxdro/Farxiga elecoglipron hMPV/RSV vaccine Launched NME Positive Phase III data for NME Note: Ambition to achieve $80bn in Total Revenue by 2030 is risk -adjusted, based on long-range plan as of AstraZeneca Investor Day May 2024. Medicines and assets listed reflect key contributors to 2030 Total Revenue ambition; however, this list is not exhaustive. Medicines and assets listed in alphabetical order and sorted by thera py area. laroprovstat previously AZD0780 and elecoglipron previously AZD5004. Collaboration partners: Daiichi Sankyo ( Enhertu, Datroway), Amgen (Tezspire), Ionis (Wainua), Merck & Co., Inc. (Lynparza). Appendix: Glossary.
Page 48
Twelve positive Phase III programme readouts YTD 49 2026 positive Phase III readouts represent >$10bn in peak year revenue3 OBERON TITANIA MIRANDA tozorakimab COPD ICANUltomiris IgAN NILEImfinzi 1L urothelial cancer CHESTNUT MULBERRY HICKORY efzimfotase alfa HPP VOLGAImfinzi MIBC SAFFRON Tagrisso + Orpathys 2-3L EGFRm NSCLC EMERALD-3Imfinzi locoregional HCC CLARITY-Gastric01 sone-ve CLDN18.2+ 2L+ gastric cancer DESTINY-Lung04Enhertu HER2m NSCLC CROSSINGTezspire EoE SANOVO1 Tagrisso + Orpathys 1L EGFRm NSCLC DeLLphi-3052Imfinzi ES-SCLC 1. SANOVO trial conducted in China. 2. DeLLphi -305 trial is sponsored by Amgen, with partial funding and Imfinzi provided by AstraZeneca. 3. Combined risk -adjusted Peak-Year Revenue of all positive Phase III programmes in 2026, including th ose depicted on the slide. Individual PYR may occur at different time points for different trials. Collaboration partners: Daiichi Sankyo ( Enhertu), Amgen (Tezspire), Hutchmed (Orpathys). Appendix: Glossary.
Page 49
Represents non-risk adjusted peak year revenue, as provided during Investor Day, May 2024 except for tozorakimab and sonesitatug vedotin which were updated at H1 and Q2 2026 results and volrustomig which was updated in September 2026. 1. Peak Year Revenue, non -risk adjusted (Product Sales and Alliance Revenue) across all indications. 2. At Investor Day, total wholly-owned ADC portfolio was presented as a >$5bn NRA PYR opportunity. Includes puxitatug samrotecan and torvutatug samrotecan, wholly-owned ADCs planned to launch by 2030. Collaboration partners: Daiichi Sankyo ( Datroway). Appendix: Glossary. 50 NMEs with pivotal data readouts before 2030 drive growth into and through the next decade Oncology BioPharma Rare Positive Phase III readout Deep late-stage pipeline of multi-blockbuster opportunities >$5bn $3-5bn efzimfotase alfa balcinrenone | zibotentan + dapagliflozin cliramitug tozorakimab saruparib volrustomig laroprovstat franchise rilvegostomig elecoglipron | AZD6234 | AZD9550 1 Wholly-Owned ADCs 2 AZD0120 surovatamig sonesitatug vedotin2
Page 50
Pipeline momentum continues through 2027 51 Key readouts support NME growth outlook >15 other high-value readouts TROPION-Lung07 | Datroway TROPION-Lung15 | Datroway ± Tagrisso PACIFIC-9 | Imfinzi + oleclumab/monalizumab reAZURE-PLUS | laroprovstat + rosuvastatin DAISY | Saphnelo IRIS | Saphnelo LAVENDER | Saphnelo TROPION-Breast03 | Datroway + Imfinzi TROPION-Breast05 | Datroway + Imfinzi PACIFIC-4 | Imfinzi CAPItello-292 | Truqap Bluestar-Endometrial01 | puxi-sam ARTEMIDE-Biliary01 | rilvegostomig eVOLVE-Cervical | volrustomig BaxPA | Baxfendy reAZURE-NAIVE | laroprovstat + rosuvastatin TILIA | tozorakimab H1 H2 Datroway laroprovstat balcinrenone/ Farxiga zibotentan/ Farxiga Etcamah saruparib AVANZAR 1L NSQ/NSQ TROP2+ NSCLC AZURE-LDL/AZURE-HeFH Dyslipidaemia BalanceD-HF HF + renal impairment ZENITH High Proteinuria CKD + high proteinuria CAMBRIA-1 HR+ eBC (adjuvant switch) EvoPAR-Prostate01 HSPC $5bn+ $5bn+ $5bn+ $5bn+ $5bn+ H1 H1 H1 H1 H2 H2 NME NRA PYR1 Oncology BioPharma 1. Represents non-risk adjusted peak year revenue for the asset, as provided during Investor Day, May 2024. 2. Combined non -risk-adjusted Peak-Year Revenue of all Phase III programmes in 2027, including those depicted on the slide. Individual PYR may occur at different time points for different trials. Collaboration partners: Daiich i Sankyo (Datroway), Innate Pharma (monalizumab). Appendix: Glossary. 2027 Phase III readouts represent potential >$20bn in non-risk-adjusted peak year revenue2
Page 51
52 Opportunity for Q&A Pascal Soriot CH IEF E XECUTI VE O FFICE R Dave Fredrickson E VP, ONCOLO GY HAE MATOL OGY BUSINE SS Sunil Verma SVP, GL OBAL HE AD, ONCOL OGY FRANCHIS E Susan Galbraith E VP, ONCOLO GY HAE MATOL OGY R& D Leora Horn SVP, L ATE DEVE LOPMENT ONCOL OGY
Page 52
Please ensure you have added the correct confidentiality statement. Type the correct statement: ‘Company Restricted’ or ‘Strictly Confidential’ . No statement is needed for public information. ! Meet AZN Management: ESMO 2026 APPENDIX
Page 53
Glossary • 1L, 2L, 3L first-, second-, third-line (a)BTC (advanced) biliary tract cancer ADC antibody-drug conjugate adj. adjuvant AE adverse event AI aromatase inhibitor AKT1 AKT serine/threonine kinase 1 AKTi AKT inhibitor ALBI Albumin-Bilirubin a/mBC advanced/metastatic breast cancer AST aspartate aminotransferase ASTCT American Society for Transplantation and Cellular Therapy ATTR-CM Transthyretin Amyloid Cardiomyopathy BCG Bacillus Calmette–Guérin BICR blinded independent central review BTD Breakthrough Designation CAR-T chimeric antigen receptor T-cells CDK4/6i cyclin-dependent kinase 4/6 inhibitor CHMP Committee for Medicinal Products for Human Use CI confidence interval CLDN18.2 Claudin-18.2 COPD chronic obstructive pulmonary disease CPS combined positive score CR complete response CRS cytokine release syndrome CRT chemoradiotherapy CSA-AKI Cardiac Surgery-Associated Acute Kidney Injury CTCAE Common Terminology Criteria for Adverse Events version 5 ctDNA circulating tumour DNA CTx chemotherapy CV cardiovascular DCO data cut-off DCR disease control rate DOR duration of response DXd deruxtecan EAC oesophageal adenocarcinoma ECOG Eastern Cooperative Oncology Group ee embolisation-eligible EFS event-free survival EGFRm epidermal growth factor receptor-mutant EoE eosinophilic oesophagitis EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire ESR1m oestrogen receptor alpha-mutated ES-SCLC extensive-stage small-cell lung cancer EV enfortumab vedotin Ex19del / Ex20ins exon 19 deletion / exon 20 insertion FISH fluorescence in situ hybridisation FLOT fluorouracil, leucovorin, oxaliplatin and docetaxel FP fluoropyrimidine FRα folate receptor alpha FSI first subject in G7 Group of Seven (major pharmaceutical markets) gBRCAm germline BRCA mutation GC gastric cancer GCG glucagon GEJ(A) / GEJC gastro-oesophageal junction (adenocarcinoma / carcinoma) GI gastrointestinal GPC3 glypican-3 HCC hepatocellular carcinoma HER2 human epidermal growth factor receptor 2 HER2-low/ultralow human epidermal growth factor receptor 2 -low/ultralow HER2m human epidermal growth factor receptor 2 -mutant HER2-/negative human epidermal growth factor receptor 2 -negative HER2+/positive human epidermal growth factor receptor 2 -positive HLR high-level results HNSCC head and neck squamous cell carcinoma HPP hypophosphatasia HR hazard ratio HR-/negative hormone receptor-negative HR+/positive hormone receptor-positive ICANS immune effector cell-associated neurotoxicity syndrome ICP tumour-associated immune cells present ICT investigator’s choice of therapy IF information fraction IgA immunoglobulin A IgAN immunoglobulin A nephropathy IHC immunohistochemistry IO immuno-oncology IQR interquartile range ITT intention-to-treat M&A mergers & acquisitions mAb monoclonal antibody mBC metastatic breast cancer mDOR median duration of response MET mesenchymal–epithelial transition factor MIBC muscle-invasive bladder cancer mNSCLC metastatic non-small cell lung cancer mOS median overall survival mPFS median progression -free survival m(PFS/OS) median (PFS/OS) mUC metastatic urothelial carcinoma NC not calculated NE not evaluable neoadj. neoadjuvant ngSERD next-generation selective oestrogen receptor degrader NME new molecular entity NMIBC non-muscle-invasive bladder cancer NMR normalised membrane ratio NR not reached NSCLC non-small cell lung cancer NSQ non-squamous NST neoadjuvant systemic treatment ORR objective response rate OS overall survival PALB2m partner and localiser of BRCA2 PARPi PARP inhibitor pCR pathological complete response PD progressive disease PD-(L)1/PD-L1 programmed cell death-(ligand) 1 PDx PD-1/PD-L1 therapeutics PFS progression-free survival PFS2 second progression-free survival PIK3CA(m) phosphatidylinositol-4–5-bisphosphate 3-kinase catalytic subunit (mutated) PPE palmar-plantar erythrodysesthesia syndrome PR partial response PRMT5i PRMT5 inhibitor PRO patient-reported outcome PRR platinum-resistant recurrence/relapse PS performance status PSR platinum-sensitive recurrent PTEN phosphatase and TENsin homolog deleted on chromosome 10 PYR peak-year revenue Q2W every 2 weeks Q3W / Q4W every 3 weeks / every 4 weeks QoL quality of life R randomised RC radical cystectomy RECIST v1.1 Response Evaluation Criteria in Solid Tumours v1.1 r/r relapsed/refractory SAE serious adverse event SAS safety analysis set SBRT stereotactic body radiotherapy SCLC small-cell lung cancer SD stable disease SERD selective oestrogen receptor degrader SoC standard-of-care SQ squamous Stg. stage tBRCAm tumour BRCA mutation TC tumour cells TCE T-cell engager TEAE / TRAE treatment-emergent / treatment-related adverse event THP docetaxel, trastuzumab and pertuzumab TIGIT T-cell immunoreceptor with immunoglobulin and ITIM domains TKI tyrosine kinase inhibitor TNBC triple-negative breast cancer TROP2 trophoblast cell surface antigen 2 TTP time to progression UC urothelial carcinoma uPR unconfirmed partial response Vp3 thrombosis in the right or left portal vein Vp4 thrombosis in the main trunk of the portal vein 54
Page 54
AstraZeneca in non-small cell lung cancer 55 Tagrisso ADAURAEGFRm ~17% IO sensitive ~75% Stg. I Metastatic 1st line 2nd line + Est. epi (G7, 2026) ~152K ~310K ~262K HER2m ~2%2 ~54K ~99K Stg. I-II Stg. III UnresectableResectable Imfinzi AEGEAN SBRT → Imfinzi PACIFIC-4 CRT → Imfinzi + monalizumab/ oleclumab PACIFIC-9 CRT → Tagrisso LAURA CRT → Imfinzi PACIFIC Stg. II-III ~70K Tagrisso ADAURA2 launched and established SoC launched indication DXd ADC IO TKI IO bispecificKey: APPEN DI X | Oncology tumour maps Datroway ± Tagrisso TROPION-Lung15 Tagrisso + Orpathys SAFFRON Zegfrovy WU-KONG1B5 Enhertu DESTINY-Lung02 Datroway TROPION-Lung17 NSQ TROP2-NMR+ Datroway TROPION-Lung05 Enhertu DESTINY-Lung04 Tagrisso +/- CTx FLAURA, FLAURA2 Zegfrovy WU-KONG285 Datroway + Tagrisso TROPION-Lung14 Imfinzi + Imjudo + CTx POSEIDON rilvegostomig ± Datroway TROPION-Lung10 rilvegostomig + CTx PD-L1≥1% AL02 (SQ)/AL03 (NSQ) rilvegostomig PD-L1≥50% ARTEMIDE-Lung04 Datroway + IO ± platinum AVANZAR/TL07/TL08 Enhertu + pembrolizumab PD-L1<50% DESTINY-Lung06 Tagrisso + Orpathys SANOVO3 Ex20ins 10% Ex20ins 10% MET-driven 10-15%4 MET-driven 34%4 TROP2+ 66% HER2+ 22% SBRT → Tagrisso PACIFIC-4 Other tumour drivers ~7%1 1. Among total NSCLC patients. 2. Among mNSCLC patients. 3. China-only trial. 4. MET-driven defined as MET IHC 3+ in 1L and MET IHC 3+ or FISH 10+ in 2L. 5. Trial sponsored by Dizal Pharma. All numbers are approximate. Illustrative settings and populations, not to scale. Lung cancer map reflects Phase III/pivotal trials. Collaboration partners: Daiichi Sankyo ( Enhertu, Datroway), Hutchmed (Orpathys). Appendix: Glossary. Zegfrovy WU-KONG163,5
Page 55
AstraZeneca in EGFRm non-small cell lung cancer 56 Exon 20 insertion mutations ~10% Exon 19 deletions / exon 21 L858R mutations ~75% Other mutations ~15% MetastaticUnresectableResectable Stg. I 1st line 2nd line +Stg. I-II Stg. IIIStg. II-III ~28K ~51K~9K ~15K~11K ~43K launched and established SoC launched indication DXd ADC IO TKI IO bispecificKey: SBRT → Tagrisso PACIFIC-4 Tagrisso ADAURA2 Tagrisso ADAURA CRT → Tagrisso LAURA Zegfrovy WU-KONG283 Tagrisso +/- CTx FLAURA, FLAURA2 Datroway + Tagrisso TROPION-Lung14 Tagrisso + Orpathys SANOVO1 MET-driven 10-15%2 Zegfrovy WU-KONG1B3 Datroway ± Tagrisso TROPION-Lung15 Tagrisso + Orpathys SAFFRON Datroway TROPION-Lung05 MET-driven 34%2 Est. epi (G7, 2026) 1. China-only trial. 2. MET-driven defined as MET IHC 3+ in 1L and MET IHC 3+ or FISH 10+ in 2L. 3. Trial sponsored by Dizal Pharma. All numbers are approximate. Illustrative settings and populations, not to scale. Lung Cancer map reflects Phase III/pivotal trials. Collaboration partners: Daiichi Sankyo ( Enhertu, Datroway), Hutchmed (Orpathys). Appendix: Glossary. Zegfrovy WU-KONG161,3 APPEN DI X | Oncology tumour maps
Page 56
AstraZeneca in breast cancer 57 RECURRENCE gBRCAm 5% of HR-positive 15% of TNBC HER2-positive 15-20% HR-positive 65-75% TNBC 10-15% Est. epi (G7, 2026) 540k 135k 100k 70k 55k 1st line 2nd line 3rd line 4th line + Early Neoadjuvant Adjuvant Metastatic CTx → Lynparza OlympiA Enhertu → THP DESTINY-Breast11 NST → residual disease → Datroway ± Imfinzi TROPION-Breast03 CTx → AI ± CDK4/6i 2-5 yrs → Etcamah CAMBRIA-1 Good outcomes with current SoC for low-risk patients CTx → Etcamah ± abemaciclib CAMBRIA-2 NST residual disease → Enhertu DESTINY-Breast05 PD-L1- 60% PD-L1+ 40%Datroway + Imfinzi TROPION-Breast04 Lynparza OlympiAD Enhertu ± pertuzumab DESTINY-Breast09 Datroway TROPION-Breast02 Datroway + Imfinzi TROPION-Breast05 Enhertu DESTINY-Breast03 Enhertu DESTINY-Breast01/02 Datroway TROPION-Breast01 Enhertu DESTINY-Breast06 HER2-low (1+, 2+) 60% HER2-ultralow (0-1+) 25% Truqap + Faslodex CAPItello291 PIK3CA, AKT1, PTEN alt. 40 % HER2-low (1+, 2+) 35% DESTINY-Breast04 HER2-low (1+, 2+) 35% Enhertu DESTINY-Breast04 HER2-low (1+, 2+) 60% launched and established SoC launched indicationDXd ADC PARPiIO ngSERD AKTiKey: APPEN DI X | Oncology tumour maps PD-L1-inelig. 70% PD-L1-elig. 30% Truqap + Faslodex + CDK4/6i CAPItello292 saruparib + Etcamah EvoPAR-Breast01 tBRCAm, PALB2m 9% AI + CDK4/6i → Etcamah + CDK4/6i SERENA-6 ESR1m 30% All numbers are approximate. Illustrative settings and populations, not to scale. Breast Cancer map reflects Phase III/pivota l trials. Collaboration partners: Daiichi Sankyo ( Enhertu, Datroway), Merck & Co., Inc. (Lynparza). Appendix: Glossary.
Page 57
AstraZeneca in gastric cancer 58 launched and established SoC launched indicationDXd ADC IO AZ ADC IO bispecificKey: APPEN DI X | Oncology tumour maps RECURRENCE Other 30-35% HER2-positive 20% Est. epi (G7, 2026) 50k 90k 60k 30k 1st line 2nd line 3rd line Early Stage II/III/IVa Advanced/Metastatic Imfinzi + perioperative FLOT in resectable disease MATTERHORN Enhertu + rilvegostomig + FP ARTEMIDE-Gastric01 Enhertu + pembrolizumab + FP DESTINY-Gastric05 Enhertu DESTINY-Gastric02, 04 Enhertu DESTINY-Gastric01 sonesitatug vedotin CLARITY-Gastric01 Claudin 18.2- positive 45-50% sonesitatug vedotin + CTx ± rilvegostomig CLARITY-Gastric02 All numbers are approximate. Illustrative settings and populations, not to scale. Gastric cancer map reflects ongoing active Phase III/pivotal trials and includes GC, EAC and GEJC epidemiology. Collaboration partner: Daiichi Sankyo ( Enhertu). Appendix: Glossary.
Page 58
AstraZeneca in bladder cancer 59 launched and established SoC launched indicationDXd ADC IO AZ ADC IO bispecificKey: APPEN DI X | Oncology tumour maps High-risk NMIBC MIBC 1L mUC 149k 81k 63k Imfinzi + BCG induction and maintenance POTOMAC Imfinzi + CTx ± Imjudo NILE Neoadjuvant Imfinzi + EV ± Imjudo → adjuvant Imfinzi ± Imjudo VOLGA Neoadjuvant Imfinzi + CTx → adjuvant Imfinzi NIAGARA Est. epi (G7, 2026) Datroway +/- rilvegostomig TROPION-Urothelial04 ~20% high-risk adjuvant All numbers are approximate. Illustrative settings and populations, not to scale. Appendix: Glossary.
Page 59
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error , please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorised use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK +44(0)203 749 5000 www.astrazeneca.com 60